Perspectives

Optimizing transfusion support for patients with MDS

Unmet needs in high-risk MDS and ongoing trials in the field

The importance of circulating tumor DNA in patients with primary CNS lymphoma

The role of immunotherapy in the AML treatment landscape

Approaching NK/T-cell lymphoma

The importance of genomics-based stratification in multiple myeloma

Managing relapse after CAR-T therapy in ALL

Triplet combinations in FLT3-mutated AML

Upcoming agents for the treatment of SCD

The current standard of care for patients with lower-risk MDS

The need for novel agents for the treatment of PTCL

The future of CLL treatment and more personalized approaches

The importance of family history in the diagnosis and management of hematological malignancies

Factors to consider when selecting myeloma patients for antibody therapy

Panobinostat for the treatment of myeloma and relevance in the UK

The potential of CAR T-cell therapy in combination with antibodies for the treatment of ALL